Skip to main content
. Author manuscript; available in PMC: 2021 Mar 15.
Published in final edited form as: Cancer. 2019 Dec 10;126(6):1339–1350. doi: 10.1002/cncr.32655

Fig. 3. The combination of an ERK inhibitor with osimertinib (A-C) or MEK inhibitor with erlotinib (D and F) or afatinib (E and F) effectively inhibits the growth of PC-9/AR xenografts in vivo.

Fig. 3.

A-C, PC-9/AR xenografts were treated with vehicle control, osimertinib (Osim), VRT752271 (VRT) or their combination starting on the same day after grouping for 22 consecutive days. D-F, PC-9/AR xenografts were treated with vehicle control, trametinib (Tram), erlotinib (Erl), afatinib (Afa), trametinib combined with erlotinib or trametinib plus afatinib starting on the same day after grouping for 24 consecutive days. Tumor sizes (A, D and E) were measured as indicated. Each measurement is mean ± SE (n = 6). At the end of treatment, mice were sacrificed to remove tumors, which were weighed (B and F). Mouse body weights were also compared (C).